✦ LIBER ✦

A double-blind and cross-over comparison of once daily doxazosin and placebo with steady-state pharmacokinetics in elderly hypertensive patients

✍ Scribed by P. J. W. Scott; J. Hosie; M. G. B. Scott

Publisher: Springer
Year: 1988
Tongue: English
Weight: 616 KB
Volume: 34
Category: Article
ISSN: 0031-6970
DOI: 10.1007/bf00614546

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of two doses of betaxolol and

Comparison of two doses of betaxolol and placebo in hypertension: A randomized, double-blind cross-over trial

✍ J. T. Salonen; R. Palminteri 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 447 KB

Double-blind, placebo-controlled compari

Double-blind, placebo-controlled comparison of zolpidem, triazolam, and temazepam in elderly patients with insomnia

✍ Ilo E. Leppik; G. Barbara Roth-Schechter; G. William Gray; Martin A. Cohn; Dougl 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

Sleep disturbances and need for hypnotics are disproportionately greater in the elderly compared to younger adults. The present study provides a placebo-controlled subjective hypnotic efficacy of zolpidem, triazolam, and temazepam in elderly insomniacs. After a single-blind placebo screening week (D

A double-blind comparison of once-daily

A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension

✍ Ming-Fong Chen; Chi-Yu Yang; Wen-Jone Chen; Chii-Ming Lee; Chau-Chung Wu; Chiau- 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 537 KB

Safety of entacapone and apomorphine coa

Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study

✍ Jan C.M. Zijlmans; Berengere Debilly; Olivier Rascol; Andrew J. Lees; Franck Dur 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## Abstract We investigated whether administration of the catechol‐__O__‐methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations. In addition, the pharmacodynamic